Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LVTX 
LAVA Therapeutics NV (LVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: LVTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.36
1 Year Target Price $1.36
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.31% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.75M USD | Price to earnings Ratio - | 1Y Target Price 1.36 |
Price to earnings Ratio - | 1Y Target Price 1.36 | ||
Volume (30-day avg) 4 | Beta 0.5 | 52 Weeks Range 0.85 - 2.00 | Updated Date 11/5/2025 |
52 Weeks Range 0.85 - 2.00 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.245 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -521.84% |
Management Effectiveness
Return on Assets (TTM) -21.3% | Return on Equity (TTM) -90.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15395793 | Price to Sales(TTM) 8.57 |
Enterprise Value -15395793 | Price to Sales(TTM) 8.57 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA 0.81 | Shares Outstanding 26305295 | Shares Floating 17407792 |
Shares Outstanding 26305295 | Shares Floating 17407792 | ||
Percent Insiders 16.8 | Percent Institutions 28.43 |
Upturn AI SWOT
LAVA Therapeutics NV
Company Overview
History and Background
LAVA Therapeutics NV is a biotechnology company focused on developing bispecific gamma-delta T cell engagers to treat cancer. Founded in 2017, it has focused on translating its innovative platform into clinical programs.
Core Business Areas
- Gamma-delta T cell engagers: LAVA develops bispecific antibodies that bind to gamma-delta T cells and tumor-associated antigens, activating the T cells to kill cancer cells.
- Clinical Programs: The company is advancing a pipeline of novel gamma-delta T cell engagers for the treatment of solid tumors and hematological malignancies.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a research and development focused organizational structure.
Top Products and Market Share
Key Offerings
- LAVA-051: A bispecific gamma-delta T cell engager targeting CD1d for the treatment of certain hematological malignancies, including multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia. Phase 1/2a clinical trial in progress. Competitors: Other companies developing bispecific antibodies and cell therapies.
- LAVA-1207: A bispecific gamma-delta T cell engager targeting EGFR for the treatment of solid tumors. Phase 1/2a clinical trial planned. Competitors: Companies developing EGFR-targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, with numerous companies developing new cancer therapies. There's a growing interest in immunotherapy and cell-based therapies.
Positioning
LAVA Therapeutics is positioned as an innovator in the field of gamma-delta T cell engagers. Its competitive advantage lies in its proprietary platform technology.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is vast, estimated in the hundreds of billions of dollars. LAVA Therapeutics is targeting specific subsets of cancers with unmet needs, positioning it to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary gamma-delta T cell engager platform
- Experienced management team
- Novel approach to cancer immunotherapy
- Early clinical data showing promise
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early stage clinical development
- High risk of clinical trial failure
- Reliance on external collaborations
Opportunities
- Potential to develop first-in-class cancer therapies
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline to new cancer targets
- Positive clinical trial results driving market value
Threats
- Competition from established cancer therapies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- AGEN
- XOMA
- GTHX
Competitive Landscape
LAVA Therapeutics competes with larger pharmaceutical companies and other biotechnology firms developing cancer immunotherapies. Its strength lies in its innovative gamma-delta T cell engager platform, but it faces challenges related to funding and clinical development.
Growth Trajectory and Initiatives
Historical Growth: LAVA Therapeutics' growth has been characterized by preclinical and early clinical development progress.
Future Projections: Future growth depends on the successful development and commercialization of its gamma-delta T cell engagers. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing its lead clinical programs (LAVA-051 and LAVA-1207) and expanding its research and development pipeline.
Summary
LAVA Therapeutics is a clinical-stage biotech company with a novel platform for developing gamma-delta T cell engagers. The company is in an early stage with no product on the market, but it has promising clinical data, an experienced team, and a clear path to commercializing their therapies. However, it is exposed to high competition and will need to manage its cash burn rate.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LAVA Therapeutics NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-25 | CEO, President & Executive Director Mr. Stephen Allen Hurly M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.lavatherapeutics.com |
Full time employees 34 | Website https://www.lavatherapeutics.com | ||
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.